Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Looks To Cross PD-1 Gap And Leap To Next-Generation IO Backbone

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline PLC isn't letting the fact that it doesn’t have a PD-1/L1 inhibitor get its immuno-oncology R&D efforts down. Instead, the company is focusing immuno-oncology research on next-generation checkpoint modulators, including the OX40 agonist antibody GSK3174998 and first-in-class ICOS agonist antibody GSK3359609, the company said during an R&D day in New York City Nov. 3.

You may also be interested in...



Walmsley Takes On Oncology: Can GSK Become A Power Player?

GlaxoSmithKline's new CEO is assembling a "dream team" to rebuild the big pharma's R&D pipeline with an emphasis on building in oncology. Walmsley outlined her strategy at J.P. Morgan, while Oncology Therapy Area Head Axel Hoos provided more details in an interview.

Pfizer’s Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise

Pfizer has reached a deal to buy Global Blood Therapeutics for $5.4bn, gaining the sickle cell therapy Oxbryta and building on efforts to reach underserved patient groups.

Pharma Braces For Potential Landmark Moment For US Drug Price Controls

US drug pricing legislation that has picked up momentum could stymie R&D investment and curb the revenue tail for some big drugs, industry says, but CEOs also expect they can navigate the challenge. 

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC030224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel